Meghan Rush, MD
Endocrinology, Diabetes & Metabolism · Colorado Springs, CONPI 1073856001
Payments from drug & device makers
Across 11 payments — averaging $27.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$105
- Amphastar Pharmaceuticals, Inc.$74
- Dexcom, Inc.$46
- Xeris Pharmaceuticals, Inc.$20
- Insulet Corporation$18
- BETA Bionics, Inc.$18
- plus $16 from 1 others
What the payments were for
- Food & beverage$299100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 3 | $105 |
| Amphastar Pharmaceuticals, Inc. | 1 | $74 |
| Dexcom, Inc. | 2 | $46 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Insulet Corporation | 1 | $18 |
| BETA Bionics, Inc. | 2 | $18 |
| Medtronic | 1 | $16 |
How this compares
$299 in reported general payments places this provider in the 25th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
See all endocrinology, diabetes & metabolism providers in Colorado →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 147 | $248,781 |
| JardianceEmpagliflozin | 52 | $75,192 |
| OzempicSemaglutide | 40 | $48,233 |
| TrulicityDulaglutide | 17 | $35,857 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $21,437 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $13,045 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $10,690 |
| Novolog FlexpenInsulin Aspart | 31 | $10,276 |
| HumalogInsulin Lispro | 18 | $8,917 |
| SynthroidLevothyroxine Sodium | 88 | $7,917 |
| NovologInsulin Aspart | 23 | $6,357 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $5,649 |
| Levothyroxine Sodium | 459 | $4,780 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $4,387 |
| Desmopressin Acetate | 11 | $3,725 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Colorado Springs
- Christina BratcherColorado Springs$23K
- Susan HenleyColorado Springs$9K
- Satish GargAurora$8.6M
- Neda RasouliAurora$6.7M
- Viralkumar ShahAurora$2.1M
- Halis AkturkAurora$1.8M
- Leigh PerreaultBoulder$1.7M
- Daniel BessesenDenver$1.2M
- Lori GerardEnglewood$786K
- Leonard ZemelDenver$728K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.